Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers

Lung Cancer

Volumn 59, Issue 2, 2008, Pages 180-191

  Li, Ying Ying ^a   Chang, John W C ^a   Chou, Wen Chi ^a   Liaw, Chuang Chi ^a   Wang, Hung Ming ^a   Huang, Jen Seng ^a   Wang, Cheng Hsu ^a   Yeh, Kun Yun ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Line 1 tumor; Non small cell lung cancer; Zoledronic acid

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; BETA GALACTOSIDASE; LIPOCORTIN 5; PROPIDIUM IODIDE; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANIMALS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHOSPHONATES; DISEASE PROGRESSION; FLOW CYTOMETRY; IMIDAZOLES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICROSCOPY, PHASE-CONTRAST; NEOPLASMS, EXPERIMENTAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 38749122501     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.08.026     Document Type: Article

References (56)

1. Berenson J., and Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid. Oncologist 9 3 (2004) 319-329
2. Kawada K., Minami H., Okabe K., Watanabe T., Inoue K., Sawamura M., et al. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy. Jpn J Clin Oncol 35 January (1) (2005) 28-33
3. Berenson J.R. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10 January (1) (2005) 52-62
4. Fromigue O., Lagneaux L., and Body J.J. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15 November (11) (2000) 2211-2221
5. Hiraga T., Williams P.J., Ueda A., Tamura D., and Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10 July (13) (2004) 4559-4567
6. Tassone P., Tagliaferri P., Viscomi C., Palmieri C., Caraglia M., D'Alessandro A., et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 88 June (12) (2003) 1971-1978
7. Forsea A.M., Muller C., Riebeling C., Orfanos C.E., and Geilen C.C. Nitrogen-containing bisphosphonates inhibit cell-cycle progression in human melanoma cells. Br J Cancer 91 August (4) (2004) 803-810
8. Kubista B., Trieb K., Sevelda F., Toma C., Arrich F., Heffeter P., et al. Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 24 June (6) (2006) 1145-1152
9. Ory B., Heymann M.F., Kamijo A., Gouin F., Heymann D., and Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104 December (11) (2005) 2522-2529
10. Corey E., Brown L.G., Quinn J.E., Poot M., Roudier M.P., Higano C.S., et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9 January (1) (2003) 295-306
11. Lee M.V., Fong E.M., Singer F.R., and Guenette R.S. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61 March (6) (2001) 2602-2608
12. Aparicio A., Gardner A., Tu Y., Savage A., Berenson J., and Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12 February (2) (1998) 220-229
13. Ural A.U., Yilmaz M.I., Avcu F., Pekel A., Zerman M., Nevruz O., et al. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol 78 December (5) (2003) 443-449
14. Jagdev S.P., Coleman R.E., Shipman C.M., Rostami H.A., and Croucher P.I. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84 April (8) (2001) 1126-1134
15. Boissier S., Magnetto S., Frappart L., Cuzin B., Ebetino F.H., Delmas P.D., et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57 September (18) (1997) 3890-3894
16. Virtanen S.S., Vaananen H.K., Harkonen P.L., and Lakkakorpi P.T. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 62 May (9) (2002) 2708-2714
17. Wood J., Bonjean K., Ruetz S., Bellahcene A., Devy L., Foidart J.M., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302 September (3) (2002) 1055-1061
18. Ullen A., Lennartsson L., Harmenberg U., Hjelm-Eriksson M., Kalkner K.M., Lennernas B., et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol (Stockholm, Sweden) 44 6 (2005) 644-650
19. Neville-Webbe H.L., Rostami-Hodjegan A., Evans C.A., Coleman R.E., and Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113 January (3) (2005) 364-371
20. Matsumoto S., Kimura S., Segawa H., Kuroda J., Yuasa T., Sato K., et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47 January (1) (2005) 31-39
21. Vogt U., Bielawski K.P., Bosse U., and Schlotter C.M. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 12 November (5) (2004) 1109-1114
22. Mountain C.F. A new international staging system for lung cancer. Chest 89 April (Suppl. 4) (1986) 225S-233S
23. Coleman R.E. Skeletal complications of malignancy. Cancer 80 October (Suppl. 8) (1997) 1588-1594
24. Bloomfield D.J. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 16 March (3) (1998) 1218-1225
25. Rosen L.S., Gordon D., Tchekmedyian S., Yanagihara R., Hirsh V., Krzakowski M., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21 August (16) (2003) 3150-3157
26. Caraglia M., D'Alessandro A.M., Marra M., Giuberti G., Vitale G., Viscomi C., et al. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene 23 September (41) (2004) 6900-6913
27. Yeh K.Y., McAdam A.J., Pulaski B.A., Shastri N., Frelinger J.G., and Lord E.M. IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes. J Immunol 160 June (12) (1998) 5773-5780
28. Yuhas J.M. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treatment Rep 63 June (6) (1979) 971-976
29. Yuhas J.M., and Li A.P. Growth fraction as the major determinant of multicellular tumor spheroid growth rates. Cancer Res 38 June (6) (1978) 1528-1532
30. Yuhas J.M., and Pazmino N.H. Inhibition of subcutaneously growing line 1 carcinomas due to metastatic spread. Cancer Res 34 January (8) (1974) 2005-2010
31. Yuhas J.M., Pazmino N.H., and Wagner E. Development of concomitant immunity in mice bearing the weakly immunogenic line 1 lung carcinoma. Cancer Res 35 January (1) (1975) 237-241
32. Kuroda J., Kimura S., Segawa H., Sato K., Matsumoto S., Nogawa M., et al. p53-Independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid. Cancer Sci 95 February (2) (2004) 186-192
33. Widrow R.J., Rabinovitch P.S., Cho K., and Laird C.D. Separation of cells at different times within G2 and mitosis by cyclin B1 flow cytometry. Cytometry 27 April (3) (1997) 250-254
34. Bahler D.W., and Lord E.M. Dimethyl sulfoxide induces expression of H-2 antigens on mouse lung carcinoma cells. J Immunol 134 April (4) (1985) 2790-2798
35. Villamarin S., Mansilla S., Ferrer-Miralles N., Priebe W., and Portugal J. A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631. Eur J Biochem/FEBS 270 February (4) (2003) 764-770
36. Hockenbery D., Nunez G., Milliman C., Schreiber R.D., and Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348 November (6299) (1990) 334-336
37. Berrieman H.K., Smith L., O'Kane S.L., Campbell A., Lind M.J., and Cawkwell L. The expression of Bcl-2 family proteins differs between nonsmall cell lung carcinoma subtypes. Cancer 103 April (7) (2005) 1415-1419
38. Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., et al. p53 Mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84 November (9) (1994) 3148-3157
39. Lotem J., and Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82 August (4) (1993) 1092-1096
40. Wada H., Asada M., Nakazawa S., Itoh H., Kobayashi Y., Inoue T., et al. Clonal expansion of p53 mutant cells in leukemia progression in vitro. Leukemia 8 January (1) (1994) 53-59
41. Burke L., Flieder D.B., Guinee D.G., Brambilla E., Freedman A.N., Bennett W.P., et al. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell-cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res 11 January (1) (2005) 232-241
42. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., and Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13 April (4) (1998) 581-589
43. Bar-Sagi D., and Hall A. Ras and Rho GTPases: a family reunion. Cell 103 October (2) (2000) 227-238
44. Salomo M., Jurlander J., Nielsen L.B., and Gimsing P. How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics. Br J Haematol 122 July (2) (2003) 202-210
45. Hirai A., Nakamura S., Noguchi Y., Yasuda T., Kitagawa M., Tatsuno I., et al. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 272 January (1) (1997) 13-16
46. Olson M.F., Paterson H.F., and Marshall C.J. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature 394 July (6690) (1998) 295-299
47. Welsh C.F., Roovers K., Villanueva J., Liu Y., Schwartz M.A., and Assoian R.K. Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat Cell Biol 3 November (11) (2001) 950-957
48. Iguchi T., Miyakawa Y., Yamamoto K., Kizaki M., and Ikeda Y. Nitrogen-containing bisphosphonates induce S-phase cell-cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal 15 July (7) (2003) 719-727
49. Kraj M., Poglod R., Maj S., Pawlikowski J., Sokolowska U., and Szczepanik J. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience). Acta Pol Pharm 59 November-December (6) (2002) 478-482
50. Berenson J., Ravera C., Ma P., Deckert F., Sasaki Y., Saeki T., et al. Population pharmacokinetics (PK) of Zometa. Proc Am Soc Clin Oncol 19 (2000) 209a [Abstract 814]
51. Croucher P., Jagdev S., and Coleman R. The anti-tumor potential of zoledronic acid. Breast (Edinburgh, Scotland) 12 August (Suppl. 2) (2003) S30-S36
52. Clezardin P. Anti-tumour activity of zoledronic acid. Cancer Treatment Rev 31 Suppl. 3 (2005) 1-8
53. Yaccoby S., Pearse R.N., Johnson C.L., Barlogie B., Choi Y., and Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116 February (2) (2002) 278-290
54. Croucher P.I., De Hendrik R., Perry M.J., Hijzen A., Shipman C.M., Lippitt J., et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18 March (3) (2003) 482-492
55. Migliorati C.A., Siegel M.A., and Elting L.S. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7 June (6) (2006) 508-514
56. Saba N., and Khuri F. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2. Clinical studies and economic analyses. Oncology 68 1 (2005) 18-22